NY State Psychiatric Institute’s Human Research Trial Suspended After Parkinson’s Drug Study Participant Committed Suicide

A human research trial at the NY State Psychiatric Institute was suspended following a participant in a Parkinson’s drug study committing suicide.

NY State Psychiatric Institute’s Human Research Trial on Parkinson’s Drug Suspended Following Participant Committing Suicide

A human research trial on the Parkinson’s drug at the NY State Psychiatric Institute, together with Columbia University, was suspended after the trial’s participant committed suicide, wherein the NY State Psychiatric Institute had been disallowed to conduct any research study involving humans as test subjects.

According to a report published in CNN, the NY State Psychiatric Institute conducted a trial for eight weeks, trying to test a Parkinson’s drug for depression on 90 human subjects aged 60 and above; however, one of the participants of the NY State Psychiatric Institute reportedly committed suicide, which led to the suspension.

The NY State Psychiatric Institute’s human research trial was reportedly led by an associate professor identified as Dr. Bret Rutherford; however, the associate professor had already resigned and never released any comment about the suspension of using human subjects at the NY State Psychiatric Institute.

READ ALSO: Weight-Loss Drug Wegovy To Increase Insurance Coverage For Obesity Drugs Following Numerous Health Benefits

NY State Psychiatric Institute Voluntarily Stops All Ongoing Studies with Humans as Test Subjects

Following the death of a participant, the NY State Psychiatric Institute voluntarily stopped all the ongoing studies with humans as the test subjects, which affected more than 400 studies.

The NY State Psychiatric Institute is under investigation after not releasing additional important details about the reported suicide of one of its trial’s participants, The New York Times reported.

READ ALSO: Protect Your Lungs With Vitamin K-Rich Foods: New Study Reveals